SNS-032 [345627-80-7]
Cat# HY-10008-200mg
Size : 200mg
Brand : MedChemExpress
SNS-032 (BMS-387032) est un inhibiteur puissant et sélectif des CDK2, CDK7 et CDK9 avec IC50 de 38 nM, 62 nM et 4 nM, respectivement. SNS-032 a un effet antitumoral.
SNS-032 (BMS-387032) ist ein potenter und selektiver Inhibitor von CDK2, CDK7, und CDK9 mit IC50s von 38 nM, 62 nM bzw. 4 nM. SNS-032 hat eine antitumorale Wirkung.
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect.
For research use only. We do not sell to patients.
SNS-032 Chemical Structure
CAS No. : 345627-80-7
This product is a controlled substance and not for sale in your territory.
Based on 6 publication(s) in Google Scholar
Description |
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1]. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||
In Vitro |
SNS-032 has low sensitivity to CDK1 and CDK4 with IC50 of 480 nM and 925 nM, respectively. SNS-032 effectively kills chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history. Compared with flavopiridol and roscovitine, SNS-032 is more potent, both in inhibition of RNA synthesis and at induction of apoptosis. SNS-032 activity is readily reversible; removal of SNS-032 reactivates RNA polymerase II, which led to resynthesis of Mcl-1 and cell survival[1]. SNS-032 inhibits three dimensional capillary network formations of endothelial cells. SNS-032 completely prevents U87MG cell–mediated capillary formation of HUVECs. In addition, SNS-032 significantly prevents the production of VEGF in both cell lines, SNS-032 prevents in vitro angiogenesis, and this action is attributable to blocking of VEGF. Preclinical studies have shown that SNS-032 induces cell cycle arrest and apoptosis across multiple cell lines[2]. SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9. SNS-032 activity is unaffected by human serum[3]. SNS-032 induces a dose-dependent increase in annexin V staining and caspase-3 activation. At the molecular level, SNS-032 induces a marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibits the expression of CDK2 and CDK9 and dephosphorylated CDK7[5]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
SNS-032 (15 mg/kg, i.p.) inhibits both xenografted BaF3-T674I cells and KBM5-T315I cells in vivo. SNS-032 abrogates the growth of tumors transplanted in nude mice with downregulation of T674I PDGFRα and T315I-Bcr-Abl[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
Molecular Weight |
380.53 |
||||||||||||
Formula |
C17H24N4O2S2 |
||||||||||||
CAS No. |
345627-80-7 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to light yellow |
||||||||||||
SMILES |
CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
|
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 62.5 mg/mL (164.24 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation |
Purity: 99.51% |
||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.6279 mL | 13.1396 mL | 26.2791 mL | 65.6978 mL |
5 mM | 0.5256 mL | 2.6279 mL | 5.2558 mL | 13.1396 mL | |
10 mM | 0.2628 mL | 1.3140 mL | 2.6279 mL | 6.5698 mL | |
15 mM | 0.1752 mL | 0.8760 mL | 1.7519 mL | 4.3799 mL | |
20 mM | 0.1314 mL | 0.6570 mL | 1.3140 mL | 3.2849 mL | |
25 mM | 0.1051 mL | 0.5256 mL | 1.0512 mL | 2.6279 mL | |
30 mM | 0.0876 mL | 0.4380 mL | 0.8760 mL | 2.1899 mL | |
40 mM | 0.0657 mL | 0.3285 mL | 0.6570 mL | 1.6424 mL | |
50 mM | 0.0526 mL | 0.2628 mL | 0.5256 mL | 1.3140 mL | |
60 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0950 mL | |
80 mM | 0.0328 mL | 0.1642 mL | 0.3285 mL | 0.8212 mL | |
100 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.6570 mL |